SEC Tracker
Get the app

Coherus Oncology CHRS

Coherus Oncology reports positive interim data

Item 7.01 Investor disclosure, Item 8.01 Other events

Form
8-K
Filed
Importance
Notable
  1. Tagmokitug in combination with toripalimab showed 75% cORR in first-line ESCC patients.
  2. PD-L1 positive patients had 100% cORR, higher than US SoC benchmark of 44%-59%.
  3. Second-line ESCC patients had 5.5 month mPFS, better than US SoC of 3.4 months.
  4. Tagmokitug showed manageable safety profile with no Grade 5 adverse events.

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Coherus Oncology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Instil Bio TIL public float $83M, Jun 30, 2025
  2. Entera Bio ENTX public float $85M, Jun 30, 2025
  3. SAB Biotherapeutics SABS public float $77M, Jun 30, 2025
  4. Vor Biopharma VOR public float $76M, Jun 30, 2025
  5. Jasper Therapeutics JSPR public float $75M, Jun 30, 2025